Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: xcentral1 who wrote (18)	2/8/2007 8:35:51 AM
From: manny t	Read Replies (2) \| Respond to of 295

Is the company ahead of schedule? From the PR: "which may then pave the way for initiating human clinical trials during 2007. The meeting results prove " Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA's acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation." "We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company's unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient's immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."